Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
25.94
-0.74 (-2.77%)
Feb 11, 2026, 4:00 PM EST - Market closed
Immunovant Market Cap
Immunovant has a market cap or net worth of $5.28 billion as of February 11, 2026. Its market cap has increased by 38.78% in one year.
Market Cap
5.28B
Enterprise Value
4.29B
1-Year Change
38.78%
Ranking
Category
Stock Price
$25.94
Market Cap Chart
Since June 21, 2019, Immunovant's market cap has increased from $124.38M to $5.28B, an increase of 4,144.92%. That is a compound annual growth rate of 75.76%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 10, 2026 | 5.43B | 5.40% |
| Dec 31, 2025 | 5.15B | 41.70% |
| Dec 31, 2024 | 3.64B | -40.34% |
| Dec 29, 2023 | 6.09B | 165.79% |
| Dec 30, 2022 | 2.29B | 134.03% |
| Dec 31, 2021 | 979.80M | -78.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 21, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Kymera Therapeutics | 6.33B |
| Caris Life Sciences | 6.29B |
| Mirum Pharmaceuticals | 6.02B |
| PTC Therapeutics | 5.95B |
| Cogent Biosciences | 5.77B |
| Structure Therapeutics | 5.46B |
| Protagonist Therapeutics | 5.20B |
| Celcuity | 4.99B |